Biological Autoimmune Therapeutics

Friday, November 16, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 15, 2018 /PRNewswire/ -- The administration of therapeutic immune modulators is becoming an increasingly important

healthcare treatment option for a growing number of diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must
successfully navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration.  Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. This report describes key factors in the trend toward user acceptance and designed-in usability. The influence of biosimilars on as-supplied packaging strategies is yet to be determined, but the need for product differentiation in an increasingly crowded market segment will make product packaging a key competitive factor.Read the full report: https://www.reportlinker.com/p05621767 What You Will Learn- What are the approved biological drugs indicated for autoimmune conditions, what is the as-supplied packaging, and who markets them?- What are the major factors driving the growth of biological drugs for treating autoimmunity?- What is the size of the market biological autoimmune therapeutics drugs today, who are the market share leaders, and what will it be in 2022?- How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?- What are the essential design factors, technologies and market development issues for biological autoimmune drugs?- What are the significant economic, technology, and regulatory factors affecting the market for immunotherapeutic drugs?Read the full report: https://www.reportlinker.com/p05621767 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/biological-autoimmune-therapeutics-300751412.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store